JP Morgan Cazenove reiterated Hikma Pharmaceuticals PLC (LON:HIK) to Overweight in a report released today.
- Updated: September 22, 2016
Yesterday Hikma Pharmaceuticals PLC (LON:HIK) traded -0.95% lower at 2,095.00GBX. The company’s 50-day moving average is 2,218.75GBX and its 200-day moving average is 2,233.92GBX. The last closing price is down -6.62% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 38,992 shares of the stock traded hands, down from an average trading volume of 550,160
JP Morgan Cazenove has reiterated Hikma Pharmaceuticals PLC (LON:HIK) to Overweight in a report released on 9/23/2016.
Previously on 09/14/2016, JP Morgan Cazenove reported on Hikma Pharmaceuticals PLC (LON:HIK) reduced the target price from 2,550.00GBX to 2,450.00GBX. At the time, this indicated a possible upside of 0.13%.
See Chart Below
Hikma Pharmaceuticals PLC has a 52 week low of 1,575.00GBX and a 52 week high of 2,703.00GBX with a P/E ratio of 25.50 The company’s market cap is currently 0 GBX.
In addition to JP Morgan Cazenove reporting its stock price target, a total of 9 brokers have issued a research note on the company. The average stock price target is 32.71GBX with 4 brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Hikma Pharmaceuticals PLC (LON:HIK)
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.